{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:25:16Z","timestamp":1787030716749,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Paclitaxel polymeric micelles (pm-Pac) are widely used for solid tumors, but real-world data on acute hypersensitivity reactions (HSRs) are limited. This exploratory study aimed to characterize the clinical features, risk factors, and dynamic laboratory changes in pm-Pac-associated acute HSRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 220 patients treated with pm-Pac from March 2023 to April 2026. Clinical data were extracted from electronic medical records. Analyses included chi-square tests, linear-by-linear association, logistic regression, and linear mixed-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall HSR incidence was 6.8% (15\/220). Most HSRs were mild-to-moderate (grade 1: 40.0%; grade 2: 33.3%) and 26.7% were grade 3. Reactions occurred predominantly within the first 60 minutes (60.0%); 88.9% of moderate-to-severe reactions (grade \u22652) occurred within this window. Fourteen events (93.3%) occurred during the second cycle, and one (6.7%) during the third cycle, with no recurrence in six patients who continued treatment. Rash and pruritus were most common manifestations, followed by cardiovascular symptoms. Conventional risk factors showed no significant associations, and routine laboratory parameters were similar between groups. Baseline autoantibody positivity was 66.7% in HSR compared with 41.2% in non-HSR patients (\n                      <jats:italic>P=<\/jats:italic>\n                      0.055). HSR severity grade was correlated with treatment outcome (\n                      <jats:italic>P=<\/jats:italic>\n                      0.001; improvement rates were 0% for grade 1, 100% for grade 2, and 66.7% for grade 3). Among evaluable patients receiving a glucocorticoid-antihistamine-calcium gluconate combination, 85.7% improved.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pm-Pac-induced acute HSRs were predominantly mild-to-moderate cutaneous reactions, occurring within the first 60 minutes and during the second cycle; grade \u22652 reactions were more frequent in the early time window. No recurrent reactions were observed in subsequent cycles. Routine laboratory monitoring did not differentiate between patients with and without HSRs; symptom surveillance is essential. Baseline autoantibody positivity showed a non-significant trend that requires validation. Given the small sample (n=15), all findings are exploratory and require confirmation in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1908304","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:28:52Z","timestamp":1787027332000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute hypersensitivity reactions to paclitaxel polymeric micelles during malignant tumor treatment: a retrospective real-world study"],"prefix":"10.3389","volume":"16","author":[{"given":"Xing","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117264","article-title":"PTX-RPPR, a conjugate of paclitaxel and NRP-1 peptide inhibitor to prevent tumor growth and metastasis","volume":"178","author":"Li","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/jbm.a.20101","article-title":"Poly(sebacic acid-co-ricinoleic acid) biodegradable carrier for paclitaxel: in vitro release and in vivo toxicity","volume":"69","author":"Shikanov","year":"2004","journal-title":"J BioMed Mater Res Part A"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2026.115720","article-title":"Reduction\/pH dual responsive micelle delivery system for cancer chemo\/photothermal \/photodynamic therapy","volume":"265","author":"Fang","year":"2026","journal-title":"Colloids Surf B Biointerfac"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27020775","article-title":"Antitumor evaluation of rhenium-188 and paclitaxel co-delivered via thermosensitive hydrogel in a hepatocellular carcinoma animal model","volume":"27","author":"Shih","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1650191","article-title":"Nab-paclitaxel versus paclitaxel for taxane acute pain syndrome in solid tumors: a systematic review and meta-analysis","volume":"15","author":"Wei","year":"2025","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100200","DOI":"10.1016\/j.ynpai.2025.100200","article-title":"Unveiling the peripheral nerve hallmarks of chemotherapy-induced neuropathy: insights from paclitaxel treatment in a murine model","volume":"18","author":"Maiar\u00f9","year":"2025","journal-title":"Neurobiol Pain"},{"key":"B7","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1177\/10781552211008503","article-title":"Hypersensitivity reactions to paclitaxel: The Mexican experience of rapid desensitization","volume":"28","author":"Gonz\u00e1lez","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.985","article-title":"Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: a retrospective cohort study","volume":"10","author":"Haine","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.Gore.2024.101475","article-title":"Safety of nab-paclitaxel following an allergic reaction to paclitaxel: A single institution retrospective study","volume":"55","author":"Kochuveettil","year":"2024","journal-title":"Gynecol Oncol Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18061018","article-title":"Paclitaxel hypersensitivity: Is titrated dosing in gynecologic oncology patients necessary","volume":"18","author":"Goldfeld","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.11.013","article-title":"Assessment of antihistamines and corticosteroids as premedication in rapid drug desensitization to paclitaxel: Outcomes in 155 procedures","volume":"6","author":"Lopez-Gonzalez","year":"2018","journal-title":"J Allergy Clin Immunol: In Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s10238-025-02035-w","article-title":"Maintaining oxaliplatin therapy after hypersensitivity reactions: real-world experience with a desensitisation protocol","volume":"26","author":"Christodoulis","year":"2026","journal-title":"Clin Exp Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.1188\/26.Cjon.E19-e25","article-title":"Prophylactic protocol for carboplatin hypersensitivity in high-risk patients with gynecologic cancer","volume":"30","author":"Cuddahy","year":"2026","journal-title":"Clin J Oncol Nurs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2015.07.017","article-title":"Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy","volume":"115","author":"Wang","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.annonc.2020.10.479","article-title":"Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial","volume":"32","author":"Shi","year":"2021","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121961","article-title":"Polymeric micellar paclitaxel (Pm-Pac) prolonged overall survival for NSCLC patients without pleural metastasis","volume":"623","author":"Lu","year":"2022","journal-title":"Int J Pharm"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.845689","article-title":"A clinical practice guideline for the emergency management of anaphylaxis (2020)","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.635","article-title":"Evaluation of anaphylactic reactions involving carboplatin and paclitaxel reported to the FDA from 1970 to 2023","volume":"190","author":"Boucher","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2\u2013","DOI":"10.3390\/jpm15010002","article-title":"Personalized risk assessment for taxane-induced hypersensitivity reactions: a systematic review and meta-analysis","volume":"15","author":"Park","year":"2024","journal-title":"J Personalized Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-023-08968-y","article-title":"Hypersensitivity reactions to taxanes: a comprehensive and systematic review of the efficacy and safety of desensitization","volume":"65","author":"Villarreal-Gonzalez","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3736-9","article-title":"Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II\/III study","volume":"156","author":"Jain","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000022814","article-title":"Mast cells activation and high blood tryptase levels due to paclitaxel administration. Is Cremophor EL the culprit?: A case report","volume":"99","author":"D'Errico","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13960","article-title":"Prospective study testing a simplified paclitaxel premedication regimen in patients with early breast cancer","volume":"26","author":"Barroso-Sousa","year":"2021","journal-title":"Oncologist"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-021-02385-x","article-title":"Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health","volume":"141","author":"Zhou","year":"2022","journal-title":"Hum Genet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.12932\/ap-050520-0831","article-title":"Characteristics of immediate hypersensitivity reaction to paclitaxel-based chemotherapy in gynecologic cancer patients","volume":"41","author":"Thangwonglers","year":"2023","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/00949655.2022.2134380","article-title":"Comparison of monotonic trend tests for some counting processes","volume":"93","author":"Pekalp","year":"2023","journal-title":"J Stat Comput Simul"},{"key":"B27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/mps9020056","article-title":"Management of patients with suspected hypersensitivity to chemotherapy drugs: a practical approach in a tertiary care setting","volume":"9","author":"Cilona","year":"2026","journal-title":"Methods Protoc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2024.16.2.123","article-title":"Understanding and challenging of taxane hypersensitivity","volume":"16","author":"Park","year":"2024","journal-title":"Allergy Asthma Immunol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08877-y","article-title":"Hypersensitivity reactions to platinum agents and taxanes","volume":"62","author":"Tsao","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.allmed.2025.100045","article-title":"An updated review of the diagnostic methods in drug hypersensitivity reactions","volume":"4","author":"Zhang","year":"2025","journal-title":"Allergy Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/all.15113","article-title":"Hypersensitivity reactions to chemotherapy: an EAACI position paper","volume":"77","author":"Pagani","year":"2022","journal-title":"Allergy"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1479","article-title":"Biases in electronic health record data due to processes within the healthcare system: retrospective observational study","volume":"363","author":"Agniel","year":"2018","journal-title":"BMJ (Clinical Res Ed)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10238-025-01780-2","article-title":"Autoantibody profiling using microarray identifies biomarkers associated with chemoimmunotherapy efficacy and immune-related adverse events in lung cancer patients","volume":"25","author":"Wang","year":"2025","journal-title":"Clin Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-25-0039","article-title":"Novel pretreatment autoantibodies correlate with enfortumab vedotin-related dermatologic events in patients with advanced urothelial cancer","volume":"5","author":"Vlachou","year":"2025","journal-title":"Cancer Res Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218796190","article-title":"Retrospective evaluation of a rechallenge protocol in patients experiencing hypersensitivity reactions with prior chemotherapy in a tertiary hospital","volume":"25","author":"Wu","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200605000-00013","article-title":"Paclitaxel hypersensitivity reactions: assessment of the utility of a test-dose program","volume":"12","author":"Henry","year":"2006","journal-title":"Cancer J"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1908304\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:28:52Z","timestamp":1787027332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1908304\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":37,"alternative-id":["10.3389\/fonc.2026.1908304"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1908304","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1908304"}}